First Trust NYSE Arca Biotechnology Index Fund
FBT
257 hedge funds and large institutions have $746M invested in First Trust NYSE Arca Biotechnology Index Fund in 2023 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 53 increasing their positions, 99 reducing their positions, and 22 closing their positions.
86% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 22
16% more capital invested
Capital invested by funds: $645M → $746M (+$101M)
6.49% more ownership
Funds ownership: 53.72% → 60.21% (+6.5%)
6% more funds holding
Funds holding: 242 → 257 (+15)
46% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 99
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$109M |
| 2 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$26.5M |
| 3 |
AAS
Ameritas Advisory Services
Lincoln,
Nebraska
|
+$6.8M |
| 4 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$4.06M |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$1.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SOS
Silver Oak Securities
Jackson,
Tennessee
|
-$61.4M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$8.56M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$7.33M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.62M |
| 5 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$4.78M |
FBT Hedge Fund Activity: Q4 2023 in Review
257 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in First Trust NYSE Arca Biotechnology Index Fund (FBT) for Q4 2023, worth a combined $746M — up 16% from $645M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new FBT positions and 22 closed out — a net gain of 19 holders — while 53 added to existing stakes and 99 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $109M. The largest seller was Silver Oak Securities, cutting an estimated $61.4M.
- 257 institutional investors held First Trust NYSE Arca Biotechnology Index Fund (FBT) as of Q4 2023, up from 242 in Q3 2023.
- Funds reported $746M of First Trust NYSE Arca Biotechnology Index Fund stock for Q4 2023, up 16% quarter-over-quarter.
- 41 funds opened new First Trust NYSE Arca Biotechnology Index Fund positions in Q4 2023 and 22 closed out, a net change of +19 holders.
- The largest First Trust NYSE Arca Biotechnology Index Fund buyer in Q4 2023 was Morgan Stanley, an estimated $109M added.
- The largest First Trust NYSE Arca Biotechnology Index Fund seller in Q4 2023 was Silver Oak Securities, an estimated $61.4M sold.
Based on aggregated 13F filings for Q4 2023.